Specifically, FGFR1 amplification occurs in approximately 19% of lung squamous cell carcinoma cases, 10% of breast cancer cases, 14% of bladder cancer cases, 10% of head and neck squamous cell carcinoma cases, and 7% of endometrial cancer cases [24]. Here, FGFR1 is linked to urinary bladder cancer.